Description

Tirzepatide 10 mg research peptide (dual GIP/GLP-1). Lyophilized, HPLC-verified. Research Use Only; not for human or veterinary use.

Peptide Tirzepetide

Short description (RUO-only)

Tirzepatide is a peptide engineered to activate both GIP and GLP-1 receptors, used by researchers to study dual incretin signaling and receptor pharmacology. Supplied as a lyophilized powder; each vial contains 10 mg research-grade material with identity/purity confirmed per COA. For laboratory research use only. Not for human or veterinary use. FDA Access Data+1

Why is it studied? Cited

• Dual incretin receptor pharmacology: Binding and signaling at GIPR/GLP-1R (cAMP, β-arrestin) and the structural basis of dual agonism. PNAS+1

• Half-life/structure–function engineering: Impact of fatty-diacid side chain and backbone design on receptor activity and exposure. PNAS

• Metabolic biology (context for mechanism): Placebo-controlled trials describe weight and glycemic endpoints—useful background for mechanistic study design (not a claim about this product). New England Journal of Medicine+1

• Identity/compound records: Public chemical identifiers and synonyms for cataloging. PubChem

RUO disclaimer: Provided exclusively for laboratory research by qualified professionals. Not intended for diagnostic, therapeutic, or household use. No dosing, safety, or efficacy claims are made.

• FDA Prescribing Information (mechanism & identity):

  • Mounjaro (tirzepatide) injection — Highlights of Prescribing Information (FDA). States tirzepatide is a GIP and GLP-1 receptor agonist. FDA Access Data

  • Zepbound (tirzepatide) injection — Prescribing Information (FDA). Current label language for obesity/OSA indications and class mechanism. FDA Access Data

• Clinical context (mechanistic background only):

  • Jastreboff et al. NEJM (SURMOUNT-1): once-weekly tirzepatide in adults with obesity; primary outcomes and safety profile. New England Journal of Medicine

  • PubMed record for SURMOUNT-1 (for easy linking). PubMed

• Structural/mechanistic studies (dual agonism):

  • Sun et al. PNAS 2022: Structural determinants of dual incretin receptor agonism (cryo-EM + MD). PNAS+1

  • Zhao et al. Nature Communications 2022: Multiplexed pharmacology with cryo-EM structures including tirzepatide–GIPR/GLP-1R complexes. Nature

• Compound identifiers:

  • PubChem: Tirzepatide compound entry (CID 156588324). PubChem